Emisphere Technologies Inc. hopes that the unwinding of its joint venture with Elan Corp. plc will actually serve to improve its position, because owning the full rights to its oral heparin products, including liquid, solid and low molecular weight formulations, could entice future partners to this large market. Moreover, the company believes it is now closer to its goal of licensing products as opposed to applications of its delivery technologies.

However, the